Company news

Puma Biotechnology Inc news in 2019

Puma Biotechnology Inc's news releases, calls and decks from 2019, newest first.

View company

CORRECTING and REPLACING Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries

December 1, 2019

Puma Biotechnology Reports Third Quarter 2019 Financial Results

November 5, 2019

FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

October 1, 2019

Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer

September 10, 2019

Decks in 2019